21 results on '"Taggart C"'
Search Results
2. 196 Airway infection and inflammation in people with cystic fibrosis treated with 1 year of elexacaftor-tezacaftor-ivacaftor—the RECOVER study
3. 505: Does the frequency of pulmonary exacerbations in CF influence the response to IV treatment?
4. ePS3.05 A neutrophilic inflammation-derived marker of disease
5. P134 Anti-inflammatory effect of liposomal loaded azithromycin in a lipopolysaccharide stimulated mouse alveolar macrophage cell line model
6. WS01.4 Antimicrobial activity of innate antimicrobial peptides against clinical cystic fibrosis respiratory isolates
7. A secretory leukocyte protease inhibitor variant with improved activity against lung infection.
8. 29 Airway epithelial cell IP-10 production is regulated by miR-31 via the transcription factor IRF-1
9. Type-I interferons induce lung protease responses following respiratory syncytial virus infection via RIG-I-like receptors.
10. 82 Effect of ivacaftor on CF clinical isolates of Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus sp. in comparison to antimicrobial peptides
11. WS19.4 Pro-inflammatory response of THP-1 monocytic cells to lipopolysaccharide from Prevotella sp. isolated from CF patients
12. 163 A role for the WFDC protein, WAP2, in the regulation of inflammatory response in the lung
13. 165 An immunomodulatory role for the serine protease inhibitor, eppin, in the lung
14. 173 Upregulated caspase activity in cystic fibrosis respiratory epithelium – a link to increased apoptosis?
15. Food Safety Guidelines vs. Traditional Low Bacteria Diet: Is there a difference in infection risk, quality of life and days of TPN following Pediatric Hematopoietic Stem Cell Transplantation (HSCT)?
16. PMD81 - Is there utility in clinical utility modeling for Diagnostic Technologies?
17. PMD63 - A Framework for coverage decisions for Digital Health Technologies.
18. 556 Evaluation of total bacterial 16S load and inflammation during intravenously treated pulmonary exacerbations in infrequent and frequent exacerbators.
19. WS13.01 Proteomic analysis of nasal lavage fluid samples in people with cystic fibrosis after one year of treatment with elexacaftor/ivacaftor/tezacaftor – the RECOVER study.
20. PRM59 - Real-World Data Utility For Health Economic Modeling: An Assessment Of Current Data Sources.
21. PMD36 - Cost effectiveness of left atrial appendage closure versus Warfarin for stroke risk reduction in non-valvular Atrial Fibrillation in CMS patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.